IntrinsicIntrinsic

Black Hawk Acquisition Corp

BKHAU
🏢 Biological Products, (No Diagnostic Substances)

Business Operations Summary

Black Hawk Acquisition Corporation (the "Company") is a blank check company, incorporated in the Cayman Islands on September 28, 2023, with the sole purpose of effecting a business combination with one or more target businesses . The Company has not commenced any operations or generated any revenues to date, with its activities focused on organizational efforts, its initial public offering (IPO), and identifying a target company for a business combination . The Company's business model is to identify and acquire a target business, providing an alternative to a traditional IPO process, which it believes is less expensive and offers greater certainty of execution . The Company aims to add value to acquired businesses by providing access to U.S. capital markets .

The Company's core business model revolves around identifying and acquiring a target business. It generates non-operating income from interest earned on marketable securities held in a trust account . The primary customer segments are not applicable as the Company is a Special Purpose Acquisition Company (SPAC) and does not have an operating business or customers. The Company's strategy is to acquire private companies with compelling economics, clear paths to positive operating cash flow, significant assets, and successful management teams seeking access to U.S. public capital markets .

The Company's management team, led by CEO, CFO, and Chairman Kent Louis Kaufman, COO and Director Jonathan Ginsberg, and Independent Directors Daniel M. McCabe and Terry W. Protto, is positioned to identify attractive risk-adjusted returns . Mr. Kaufman has over 30 years of experience in executive roles, management consulting, and executive coaching, having worked with major companies like NVIDIA, Amazon, Google, and Apple . Mr. Ginsberg has experience in education services, technology, and international trade . Mr. McCabe has a legal background and board experience with other SPACs, Yotta Acquisition Corporation and Quetta Acquisition Corporation . Mr. Protto has extensive leadership experience in retail, manufacturing, and consulting, including growing a mail order business to approximately $250 million in annual revenue and serving as CEO/President of Alpine 4 Holdings, Inc. . The Company leverages its management's industry relationships and professional network for deal sourcing .

For the fiscal year ended November 30, 2025, the Company reported net income of $1,329,557 . This was primarily driven by interest income of $2,244,975 (comprising $1,798 in general interest income and $2,258,631 in interest earned on investments held in the Trust Account ) and a change in fair value of derivative liability of $92 . These were offset by general and administrative expenses of $795,510 and related party administrative fees of $120,000 . As of November 30, 2025, the Company had cash of $39,521 and investments held in the Trust Account of $23,827,149 . Total current liabilities were $1,482,233 , including $575,000 due to the target company , $296,410 in accrued offering costs and expenses , $15,454 in accrued interest expenses , and $595,369 in convertible notes – related party . The Company also had a deferred underwriting fee payable of $2,415,000 . The working capital deficit as of November 30, 2025, was $1,431,443 . Basic and diluted net income per share for Class A ordinary shares subject to possible redemption was $0.19 , and for non-redeemable Class A ordinary shares was also $0.19 .

Comparing fiscal year 2025 to 2024, net income decreased from $1,915,703 in 2024 to $1,329,557 in 2025. Interest earned on investments held in the Trust Account decreased from $2,484,264 in 2024 to $2,258,631 in 2025. General and administrative expenses increased from $492,131 in 2024 to $795,510 in 2025, and related party administrative fees increased from $83,945 in 2024 to $120,000 in 2025. The Company also incurred interest expense of $15,454 in 2025, which was not present in 2024. Cash decreased significantly from $264,842 in 2024 to $39,521 in 2025, and investments held in the Trust Account decreased from $71,829,264 in 2024 to $23,827,149 in 2025, largely due to redemptions.

During the reported period, the Company entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. and BH Merger Sub, Inc. on April 26, 2025, to consummate a business combination . Vesicor is a California-based early development stage biotechnology corporation focused on p53-based cancer therapeutics . The transaction values Vesicor at a pre-money equity value of $70 million . On July 8, 2025, shareholders approved an extension of the business combination deadline, allowing monthly extensions through December 22, 2026, subject to $150,000 monthly deposits into the Trust Account . In connection with this extension, holders of 4,775,923 public ordinary shares exercised their redemption rights, resulting in a payment of approximately $51.0 million from the Trust Account and leaving approximately $22.7 million remaining in the Trust Account . The Company also issued convertible promissory notes to the Sponsor, drawing $350,000 under the June Note and $250,000 under the September Note as of November 30, 2025 .

Business Outlook & Future Growth Drivers

The Company intends to use substantially all of the net proceeds from its IPO and private placement, including funds in the Trust Account, to complete its initial business combination and cover related expenses, such as deferred underwriting discounts and commissions . Any remaining proceeds in the Trust Account, along with other net proceeds not expended, will be used as working capital to finance the operations of the target business, potentially for expansion, strategic acquisitions, marketing, research and development, or to repay operating expenses . The Company expects to continue incurring significant professional costs as a public company and transaction costs in pursuing the business combination .

The Company has entered into a Business Combination Agreement with Vesicor Therapeutics, Inc., a California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles . The transaction values Vesicor at a pre-money equity value of $70 million . Existing Vesicor shareholders and management will roll over 100% of their equity into the combined company and will not receive any cash proceeds . The completion of this Business Combination is subject to regulatory approvals, shareholder approvals from both Black Hawk and Vesicor, and other customary closing conditions, including Nasdaq listing approval .

The Company's shareholders approved an extension of the deadline to consummate a business combination, allowing for monthly extensions from June 22, 2025, through December 22, 2026 . Each one-month extension requires a deposit of $150,000 into the Trust Account . The extension payments due in December 2025 and January 2026 were funded after their respective due dates, and as of the financial statement issuance date, the Company is current with these payments . In December 2025, the Company drew the remaining $100,000 balance of the September Convertible Note . Between December 2025 and February 28, 2026, Vesicor contributed a total of $350,000 as extension fees . On February 12, 2026, the Company issued a convertible note to the Sponsor for up to $300,000 for working capital and extension fees, which was fully drawn as of February 28, 2026 .

The Company's capital allocation plans include using funds from its IPO and private placement for the business combination and related expenses . The deferred underwriting commission of $2,415,000 is payable upon the closing of a business combination from the Trust Account . The Sponsor or its affiliates may loan the Company funds for transaction costs or to extend the combination period, with certain loans convertible into ordinary shares at $1.00 per share . The Company also pays its Sponsor $10,000 per month for office space and administrative services .

The Company's management has determined that its current liquidity needs and the uncertainty of completing a business combination within the Combination Period raise substantial doubt about its ability to continue as a going concern . The Company's ability to consummate a business combination or the operations of a target business may be materially and adversely affected by various social and political circumstances, including rising trade tensions and global conflicts . The ability to raise equity and debt financing may also be impacted by increased market volatility or decreased market liquidity .

Major Risk Factors & Challenges

The Company faces material risks related to its ability to continue as a going concern, primarily due to its current liquidity needs and the uncertainty of completing a business combination within the prescribed Combination Period . If the Company fails to complete a business combination by December 22, 2026, it will redeem its public shares and liquidate . The redemption price for public shareholders will depend on the funds remaining in the trust account, and there is no assurance that sufficient funds will be available if creditor claims take priority . The proceeds in the trust account could be subject to claims of creditors, potentially reducing the per-share redemption amount below $10.05 . The Sponsor has agreed to be liable for claims that reduce the trust account below $10.05 per public share , but the Company has not independently verified the Sponsor's ability to satisfy these obligations, and the Sponsor's only assets are securities of the Company . Additionally, the Company's disclosure controls and procedures were not effective as of November 30, 2025, due to inadequate segregation of duties and insufficient written policies, which could lead to errors or fraud in financial reporting . Global social and political circumstances, including trade tensions and international conflicts, may adversely affect the Company's ability to consummate a business combination or the operations of a target business, and may impact its ability to raise financing .

Management Priorities & Sentiments

Management's message emphasizes the Company's status as a blank check company formed to effect a business combination, highlighting its ongoing efforts to identify and evaluate acquisition candidates. The Company has entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. on April 26, 2025, valuing Vesicor at a pre-money equity value of $70 million , and is focused on consummating this transaction. A key strategic priority is to successfully complete this business combination, which is subject to customary closing conditions including regulatory and shareholder approvals . Management has also secured an extension of the business combination deadline through December 22, 2026, requiring monthly deposits of $150,000 into the Trust Account , demonstrating a commitment to extending the search period. Another strategic priority is to address the Company's liquidity needs and going concern considerations, as management has determined that current conditions raise substantial doubt about its ability to continue as a going concern . Management plans to improve internal control over financial reporting by expanding and improving review processes for complex securities and accounting standards, enhancing access to accounting literature, and considering additional staff .

References

  1. [1] Item 1, Business Overview
  2. [2] Item 7, MD&A — Results of Operations
  3. [3] Item 1, Business — Status as a Publicly Listed Acquisition Company
  4. [4] Item 1, Business — Business Strategies
  5. [5] Item 7, MD&A — Results of Operations
  6. [6] Item 1, Business — Business Strategies
  7. [7] Item 1, Business — Competitive Advantages
  8. [8] Item 1, Business — Leadership of an Experienced Management Team and Board of Directors
  9. [9] Item 1, Business — Leadership of an Experienced Management Team and Board of Directors
  10. [10] Item 1, Business — Leadership of an Experienced Management Team and Board of Directors
  11. [11] Item 1, Business — Leadership of an Experienced Management Team and Board of Directors
  12. [12] Item 1, Business — Established Deal Sourcing Network
  13. [13] Item 7, MD&A — Results of Operations
  14. [14] Item 7, MD&A — Results of Operations
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Liquidity and Capital Resources
  21. [21] Item 7, MD&A — Liquidity and Capital Resources
  22. [22] Item 7, MD&A — Consolidated Balance Sheets
  23. [23] Item 7, MD&A — Consolidated Balance Sheets
  24. [24] Item 7, MD&A — Consolidated Balance Sheets
  25. [25] Item 7, MD&A — Consolidated Balance Sheets
  26. [26] Item 7, MD&A — Consolidated Balance Sheets
  27. [27] Item 7, MD&A — Consolidated Balance Sheets
  28. [28] Item 7, MD&A — Liquidity and Capital Resources
  29. [29] Item 7, MD&A — Consolidated Statements of Operations
  30. [30] Item 7, MD&A — Consolidated Statements of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Liquidity and Capital Resources
  36. [36] Item 7, MD&A — Liquidity and Capital Resources
  37. [37] Item 1, Business Overview
  38. [38] Item 7, MD&A — Overview
  39. [39] Item 7, MD&A — Business Combination Agreement
  40. [40] Item 1, Business — Initial Business Combination
  41. [41] Item 1, Business — Initial Business Combination
  42. [42] Item 1, Business — Initial Business Combination
  43. [43] Item 1, Business — Initial Business Combination
  44. [44] Item 1, Business — Initial Business Combination
  45. [45] Item 1, Business — Initial Business Combination
  46. [46] Item 7, MD&A — Convertible Notes — Related Party
  47. [47] Item 7, MD&A — Convertible Notes — Related Party
  48. [48] Item 7, MD&A — Convertible Notes — Related Party
  49. [49] Item 7, MD&A — Liquidity and Capital Resources
  50. [50] Item 7, MD&A — Liquidity and Capital Resources
  51. [51] Item 7, MD&A — Liquidity and Capital Resources
  52. [52] Item 1, Business Overview
  53. [53] Item 7, MD&A — Business Combination Agreement
  54. [54] Item 7, MD&A — Business Combination Agreement
  55. [55] Item 7, MD&A — Extension Payment
  56. [56] Item 7, MD&A — Subsequent Events
  57. [57] Item 7, MD&A — Subsequent Events
  58. [58] Item 7, MD&A — Subsequent Events
  59. [59] Item 7, MD&A — Subsequent Events
  60. [60] Item 7, MD&A — Subsequent Events
  61. [61] Item 7, MD&A — Subsequent Events
  62. [62] Item 7, MD&A — Contractual Obligations
  63. [63] Item 7, MD&A — Related Party Loans
  64. [64] Item 7, MD&A — Administrative Services Agreement
  65. [65] Item 7, MD&A — Administrative Services Agreement
  66. [66] Item 7, MD&A — Liquidity and Capital Resources
  67. [67] Item 7, MD&A — Risks and Uncertainties
  68. [68] Item 7, MD&A — Risks and Uncertainties
  69. [69] Item 1, Business — Redemption of public shares and liquidation if no initial business combination
  70. [70] Item 1, Business — Initial Business Combination
  71. [71] Item 1, Business — Redemption of public shares and liquidation if no initial business combination
  72. [72] Item 1, Business — Redemption of public shares and liquidation if no initial business combination
  73. [73] Item 1, Business — Redemption of public shares and liquidation if no initial business combination
  74. [74] Item 9A, Controls and Procedures — Evaluation of Disclosure Controls and Procedures
  75. [75] Item 9A, Controls and Procedures — Management’s Annual Report on Internal Control over Financial Reporting

Report on May 20, 2026